Development of functional aptamers as a comprehensive therapeutic agent for cardiovascular disease
| Project/Area Number |
17K08968
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Showa University (2019)
Kurume University (2017-2018) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | DNAアプタマー / グリセルアルデヒド由来ピリジニウム / 終末糖化産物 / GLAPアプタマー / AGEsアプタマー / PEDF受容体 / アプタマー / PEDF / ラミニン受容体 |
|---|
| Outline of Final Research Achievements |
Advanced glycation end products (AGEs) are proteins formed by non-enzymatic glycation of free amino groups by sugars and aldehydes, and accumulation of AGEs is associated with the development and progression of various age-related diseases. We found that glyceraldehyde-derived pyridinium (GLAP) and fructose-derived AGEs induced inflammatory responses in vascular endothelial cells and renal proximal tubular epithelial cells through generation of oxidative stress. In addition, we developed DNA aptamers that can bind to GLAP or AGEs, and demonstrated that these aptamers inhibited inflammatory responses induced by GLAP and AGEs.
|
| Academic Significance and Societal Importance of the Research Achievements |
人口が高齢化しつつある我が国において、老年病への対策は重要な問題となっている。DNAアプタマーは、抗体医薬品に比ベて安価で、大量に調整もできることから、次世代のバイオ医薬品として注目を集めている。本研究によって、グリセルアルデヒド由来ピリジニウムやAGEsと結合してその機能を阻害するDNAアプタマーの有用性が示され、包括的に老年病を制御する治療法の開発につながると予想される。
|
Report
(4 results)
Research Products
(23 results)
